See more : Sandoz Group AG (0SAN.L) Income Statement Analysis – Financial Results
Complete financial analysis of SpringWorks Therapeutics, Inc. (SWTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SpringWorks Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- STRATA Skin Sciences, Inc. (SSKN) Income Statement Analysis – Financial Results
- Sparinvest INDEX Europa Growth KL (SPIEUGKL.CO) Income Statement Analysis – Financial Results
- Electra Battery Materials Corporation (18P.F) Income Statement Analysis – Financial Results
- Long4life Limited (L4L.JO) Income Statement Analysis – Financial Results
- McFarlane Lake Mining Limited (MLMLF) Income Statement Analysis – Financial Results
SpringWorks Therapeutics, Inc. (SWTX)
About SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 5.45M | 6.15M | 0.00 | 35.00M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 422.00K | 1.90M | 490.00K | 349.00K | 192.00K | 17.33K | 3.18K |
| Gross Profit | 5.03M | 4.25M | -490.00K | 34.65M | -192.00K | -17.33K | -3.18K |
| Gross Profit Ratio | 92.25% | 69.16% | 0.00% | 99.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 150.49M | 146.12M | 101.68M | 51.86M | 42.55M | 9.90M | 2.80M |
| General & Administrative | 197.55M | 134.55M | 71.79M | 29.47M | 16.69M | 8.59M | 5.58M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.73M |
| SG&A | 197.55M | 134.55M | 71.79M | 29.47M | 16.69M | 8.59M | 1.86M |
| Other Expenses | 0.00 | -138.00K | -152.00K | 25.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 348.04M | 280.67M | 173.47M | 81.32M | 59.24M | 18.49M | 4.66M |
| Cost & Expenses | 348.46M | 280.67M | 173.47M | 81.32M | 59.24M | 18.49M | 4.66M |
| Interest Income | 22.95M | 6.15M | 698.00K | 1.33M | 3.55M | 678.00K | 63.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.67M | 1.90M | 490.00K | 349.00K | 192.00K | 17.33K | 3.18K |
| EBITDA | -341.35M | -280.67M | -172.98M | -45.98M | -59.05M | -18.47M | -4.64M |
| EBITDA Ratio | -6,266.68% | -4,566.03% | 0.00% | -131.36% | 0.00% | 0.00% | 0.00% |
| Operating Income | -343.01M | -280.67M | -173.47M | -46.32M | -59.24M | -18.49M | -4.66M |
| Operating Income Ratio | -6,297.28% | -4,566.03% | 0.00% | -132.35% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 17.91M | 3.26M | -442.00K | 750.00K | 933.00K | 678.00K | 21.00K |
| Income Before Tax | -325.10M | -277.42M | -173.91M | -45.57M | -58.31M | -17.81M | -4.64M |
| Income Before Tax Ratio | -5,968.50% | -4,513.05% | 0.00% | -130.21% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.26M | -698.00K | -1.33M | -3.55M | 678.00K | -2.00 |
| Net Income | -325.10M | -274.16M | -173.21M | -44.24M | -54.76M | -17.81M | -4.64M |
| Net Income Ratio | -5,968.50% | -4,460.06% | 0.00% | -126.41% | 0.00% | 0.00% | 0.00% |
| EPS | -5.15 | -5.14 | -3.57 | -1.02 | -1.27 | -0.80 | -0.11 |
| EPS Diluted | -5.15 | -5.14 | -3.57 | -1.02 | -1.27 | -0.80 | -0.11 |
| Weighted Avg Shares Out | 63.12M | 53.29M | 48.50M | 43.30M | 43.01M | 22.20M | 43.23M |
| Weighted Avg Shares Out (Dil) | 63.12M | 53.29M | 48.50M | 43.30M | 43.01M | 22.20M | 43.23M |
SpringWorks Therapeutics: How A Likely FDA Approval Can Kickstart The Stock's Repricing Potential
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer
SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
SpringWorks Therapeutics: FDA Decision Date Ahead
SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
US FDA delays decision on SpringWorks Therapeutics' tumor treatment
SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA
SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
Source: https://incomestatements.info
Category: Stock Reports